Meet inspiring speakers and experts at 3000+ global Conference Series annual meetings.
(PRWEB) September 26, 2016
With its 3000+ global events, including 1000+ scientific conferences, and 2000+ International workshops, seminars, exhibitions and symposia, Conference Series is all set to offer a global platform for discussion and knowledge sharing on the growing cancer menace across America, Europe, the Middle East, and Asia Pacific during 2016- 2017.
Cancer is no longer a rare disease confined to the high income generating nations alone. It is the second leading cause of death worldwide and the growing number of cancer incidences across the globe is a major health concern. In 2013, around 14.1 million new cases and approximately 8.2 million cancer deaths has been reported. This number is anticipated to rise up to 20% by 2010-2030, primarily due to aging and increased exposure to the risk factors leading to cancer. Breast cancer, blood cancer, liver cancer, and stomach cancer account for nearly half of global cancer deaths.
The global cancer diagnostics market was estimated to be USD $101.0 billion in 2013; it is estimated to reach a CAGR of 7.6% during 2014-2020. Similarly, the cancer biomarkers market is expected to reach USD $15,973.8 Million by 2020. In 2010, the overall cancer care industry was valued at $54 billion, which is forecasted to reach $81 billion by 2016. USA, France, Germany, Italy, Spain, United Kingdom and Japan were the seven affected regions, representing 79% of the affected population (worth $43 billion) in 2010.
The social impact of cancer on American society is immense. By 2017, approximately 2,245,110 new cases of cancer will be diagnosed in the US alone with a high mortality rate, as 595,690 may die from it. The number of people living with cancer reached nearly 14.5 million in 2014 and is predicted to reach 19 million by 2024. The American cancer care industry was worth $125 billion in 2010 and it is expected to reach $156 billion in 2020.
In the Middle-East, the cancer diagnostics and therapeutics market as of now is estimated to have been worth $467.04 million in 2015 and is anticipated to achieve USD $4 billion by 2020 with a development rate of 13%. For instance, almost 50% of breast cancer patients in the Middle East are diagnosed at a median age of 49-52, compared to a median age of 63 in Western countries.
According to the World Health Organization, Asia's prevalence of cancer deaths may climb from 45% to 163%, which is approximately 100,000 people by 2030. The rate of cancer cases in Asia may jump by almost 60% to 7.1 million new cases a year by 2020. The incidence of cancer cases is estimated to increase from 6.1 million in 2008 to 10.6 million in 2030, due to aging and growing populations, lifestyle and socioeconomic changes.
To provide global platforms for discussion and knowledge exchange among the well renowned researchers and scientists concerning cancer, Conference Series is organizing oncology meetings every year on a wide range of cancer topics. Many of the important and informative cancer research topics are discussed at these conferences. The scientific sessions of these international conferences include discussion about the diseases such as breast cancer, blood cancer, pancreatic cancer, oral cancer, prostate cancer, liver cancer, and their prevention and similar or concurrent diagnosis as well as treatment based sessions related to biomarkers, cancer drugs, radiology, anti-cancer therapy, surgery and transplantations.
About Conference Series
Conference Series, and its partner OMICS Group's open access journal publishers, owns and operates 700 peer reviewed journals, is visited by 30 million online visitors, and is supported by 1000+ scientific and business collaborations. The majority of the international conferences organized by Conference Series provide CME, CE and CPD credits. At these CME oncology conferences and CME radiology meetings, distinguished speakers from different parts of the world deliver vital and thought-provoking talks on all key topics, unveiling the recent innovations in cancer research.
Oncology Conference Series